Solvonis is so sexy right now12 Jan 2026 08:58
On R&D, the professional services firm has urged drugmakers to redirect their pipelines toward urgent and undertreated diseases, bidding companies to “move beyond incremental improvements in crowded categories.” PwC singled out reversing organ decline, curing genetic conditions and extending health lifespans as particularly enticing targets.
To get there, the pharma industry should pool internal expertise with biotech “trailblazers,” AI discovery platforms, venture incubators and academic institutions, PwC advised.